

GLAXOSMITHKLINE PLC
Form 6-K
July 14, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 14 July 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

- b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.2165	91
n/a (single transaction)	

- d) Aggregated information
Aggregated volume Price

- e) Date of the transaction 2017-07-13
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr I W Whyte
- b) Position/status PCA of Mrs V A Whyte (Company Secretary)
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence
 each ('Ordinary Shares')
 ISIN: GB0009252882
 Acquisition of Ordinary
 Shares following the
 b) Nature of the transaction re-investment of dividends
 paid to shareholders on 13
 July 2017.
 c) Price(s) and volume(s) Price(s) Volume(s)
 £16.2165 498
 n/a (single transaction)

- d) Aggregated information
 Aggregated volume Price

- e) Date of the transaction 2017-07-13
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs D Connor
 PCA of Mr R G Connor
 b) Position/status (President, Global
 Manufacturing & Supply)
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence
 each ('Ordinary Shares')
 ISIN: GB0009252882
 b) Nature of the transaction Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 13

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

July 2017.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.2165	236
	n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction	2017-07-13
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 14, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc